Skip to main content
. 2020 May 9;12(5):1198. doi: 10.3390/cancers12051198

Figure 5.

Figure 5

Tube formation assay; (A) Ctrl; (B) IL 1:50; (C) MIX 1:50; (D) IL MIX 1:50; (E) 6 h viability inhibition on HUVEC; (F) quantification of tube forming assay (6 h); ** IL MIX vs. MIX p < 0.01. IL: Intralipid®; MIX: combination of drugs; IL MIX: MIX co-loaded in IL.